Related Experiment Videos

Doxacurium pharmacodynamics in children during volatile and opioid-based anaesthesia

C Kern1, E Tassonyi, J C Rouge

  • 1Department of Anaesthesiology, Geneva University Hospital, Switzerland.

Anaesthesia
|April 1, 1996
PubMed

Insights

In children aged 2-10 years, both halothane and isoflurane enhanced doxacurium

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • The interaction between neuromuscular blocking agents like doxacurium and common anesthetic agents is crucial for pediatric surgical procedures.
  • Limited data exists on the potentiation effects of halothane, isoflurane, and alfentanil on doxacurium in pediatric populations.

Purpose of the Study:

  • To investigate and compare the dose-response effects of doxacurium when co-administered with halothane, isoflurane, or alfentanil in pediatric anesthesia.
  • To determine the effective dose 50 (ED50) and effective dose 90 (ED90) of doxacurium under different anesthetic regimens in children.

Main Methods:

  • A cumulative dose-response study utilizing electromyography was conducted in pediatric patients aged 2-10 years.
  • Patients received anesthesia supplemented with either halothane (n=9), isoflurane (n=12), or alfentanil (n=9) alongside nitrous oxide/oxygen.
  • Doxacurium doses were incrementally administered to achieve specific levels of neuromuscular blockade.

Main Results:

  • Both isoflurane and halothane significantly potentiated the neuromuscular blocking effects of doxacurium compared to alfentanil.
  • The ED50 of doxacurium was lower with halothane (23.9 µg/kg) than with alfentanil (32.7 µg/kg).
  • The ED90 of doxacurium was lower with isoflurane (32.7 µg/kg) than with alfentanil (48.2 µg/kg), indicating increased potency (p < 0.05).

Conclusions:

  • Inhalational anesthetics (halothane, isoflurane) increase doxacurium potency in pediatric patients compared to alfentanil.
  • Anesthesiologists should consider these potentiating effects when calculating doxacurium doses for pediatric patients receiving these anesthetic agents.
  • The duration of neuromuscular block was comparable across groups when equipotent doses were used, suggesting predictable recovery profiles once doses are adjusted for potency.

Related Concept Videos